Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns. Tryp’s efforts come as the Drug Enforcement Administration (“DEA”) recently “proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medication. The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogen substances are regulated.”
To view the full article, visit https://ibn.fm/A5Z4G
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
